Continuing momentum in its biosimilars portfolio, Fresenius Kabi announces that the US FDA has accepted for review regulatory applications for the proposed intravenous vedolizumab biosimilar. This biosimilar is intended to expand treatment options for patients with inflammatory bowel conditions, including ulcerative colitis and Crohn’s disease.